Abstract Background: HER2 (human epidermal growth factor receptor 2) overexpression is a pivotal biomarker for breast cancer prognosis and targeted therapy selection. Conventional assessment requires immunohistochemistry (IHC) and/or in situ hybridization (ISH), which are costly, time-consuming, and constrained by limited tissue and resource availability. In contrast, hematoxylin-and-eosin (H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5470.
Building similarity graph...
Analyzing shared references across papers
Loading...
Ziyu Su
Abdul Akbar
Usama Sajjad
Cancer Research
The Ohio State University
The Ohio State University Wexner Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Su et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fc8ea79560c99a0a2375 — DOI: https://doi.org/10.1158/1538-7445.am2026-5470